Latest Media Releases (Page 12) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SUDA Results of AGM (ASX:ALA)

Details of resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary. All discretionary votes were in favour of the chair and were voted in favour ...read more

SUDA AGM Presentation (ASX:ALA)

Observations from the Chair The technology is sound Solid barriers to entry as evidenced by our partners’ willingness to engage Shareholder sentiment at an all time...read more

SUDA Management Changes (ASX:ALA)

The US based business development role, headed by Andrew Curtis, will cease in 30 days time. This function will be assumed by the incoming CEO and the Company’s international business dev...read more

SUDA Further Outlines Case For Share Consolidation And Appendix 3A.3 (ASX:ALA)

SUDA Pharmaceuticals Limited (ASX: SUD), a leader in oro-mucosal drug delivery, has attached its Appendix 3A.3: Notification of reorganisation of capital, being a proposed 1-for-25 share consolida...read more

SUDA Pharmaceuticals Appendix 4C for the consolidated Group for Q1 of FY20 (ASX:ALA)

SUDA Pharmaceuticals Limited (ASX:SUD), a leader in oro-mucosal drug delivery, released its Appendix 4C for the consolidated Group for the first quarter of FY 2020. For more information, do...read more

SUDA Pharmaceutical inalises Agreement with Cann Pharmaceutical Australia (ASX:ALA)

Key points: SUDA enters into a fully funded development, licence and supply agreement with Cann Pharmaceutical Australia Ltd (CPA); SUDA will optimise its OroMist® oro-mucosal spray techno...read more

SUDA Pharmaceuticals Finalises Agreement with Cann Pharmaceutical Australia (ASX:ALA)

Suda Pharmaceutical's response to ASX queries (ASX:ALA)

In regards to the ASX's letter of 27 September 2019 in relation to Queries regarding Accounts, please find Suda Pharmaceutical's responses in the attached PDF.

SUDA Pharmaceuticals Announce Managing Director & CEO Resignation (ASX:ALA)

Perth, Australia – 24 September 2019: SUDA Pharmaceuticals Limited (ASX: SUD), a leader in oro-mucosal drug delivery, advises that Managing Director and Chief Executive Officer, Mr Stephen Carte...read more

Suda Pharmaceuticals preliminary final report (ASX:ALA)

The current reporting period is the financial year ended 30 June 2019. For more information, download the attached PDF.

SUDA Pharmaceuticals release Article on Anagrelide (ASX:ALA)

Article on Anagrelide PERTH, AUSTRALIA - 29 August 2019; SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oro-mucosal drug delivery ("SUDA"). is pleased to announce that Research Outreach ...read more

SUDA Pharmaceuticals ArTiMist Appeal Lodged with TGA (ASX:ALA)

SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, has lodged its appeal with the Australian Therapeutic Goods Administration against the notice of denial for marketing app...read more

SUDA Pharmaceuticals ZolpiMist Clinical Results (ASX:ALA)

SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, is pleased to announce ZolpiMist Clinical Study Results Demonstrating Lingual Spray Delivers More Rapid Sleep Onset Compare...read more

AusCann Announce June 2019 Quarterly Activities and Cashflow Reports (ASX:AC8)

AusCann strengthens strategic partnerships during June Quarter Highlights Commencement of Mr Ido Kanyon as new CEO of AusCann First commercial shipment of medical cannabis concentrate...read more

SUDA Pharmaceuticals Appendix 4C for the consolidated Group for the final quarter of FY2019. (ASX:ALA)

SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the final quarter of FY2019. For more information, downl...read more

Viewing: 166 - 180 of 200 Previous | Next